首页> 外文OA文献 >A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

【2h】

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

机译：连续Erlotinib加吉西他滨或吉西他滨的多中心随机开放标签期II试验作为ECOG PS2患者的先进非小细胞肺癌患者的一线治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
M. MICHAEL; N. PAVLAKIS; P. CLINGAN; R. DE BOER; M. JOHNSTON; S. CLARKE;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer [J] . MichaelM., PavlakisN., ClinganP., Oncology reports . 2012,第3期

机译：连续厄洛替尼联合吉西他滨或吉西他滨作为一线治疗在ECOG PS2晚期非小细胞肺癌患者中的多中心随机开放临床II期试验
3. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC [J] . Michael Michael, White Shane C., Abdi Ehtesham, Asia-Pacific journal of clinical oncology . 2015,第Pta1期

机译：序贯厄洛替尼和吉西他滨与吉西他滨单药作为一线治疗老年或ECOG PS的两名晚期NSCLC患者的多中心随机，开放式II期试验
4. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age >/=70 years) with stage IIIB/IV non-small cell lung cancer. [J] . Stinchcombe TE, Peterman AH, Lee CB, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2011,第9期

机译：吉西他滨，厄洛替尼或吉西他滨或厄洛替尼一线治疗在一线IIIB / IV期非小细胞肺癌的老年患者中的随机II期临床试验。
5. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
6. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
7. A multi-centre randomized open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer [O] . M. MICHAEL, N. PAVLAKIS, P. CLINGAN, -1

机译：连续厄洛替尼联合吉西他滨或吉西他滨作为一线治疗在ECOG PS2晚期非小细胞肺癌患者中的多中心随机开放试验II期试验
8. A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer [O] . Stinchcombe Thomas E., Peterman Amy H., Lee Carrie B., 2011

机译：吉西他滨，厄洛替尼或吉西他滨和厄洛替尼一线治疗IIB / IV期非小细胞肺癌老年患者的随机二期试验

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

著录项

相似文献

相关主题

期刊订阅